Transforming growth factor beta and its receptors (TGF-beta/TGFBR)

Transforming growth factor beta (TGF-beta) and its receptors (TGFBR1, TGFBR2, and TGFBR3) constitute a critical signaling axis that regulates a wide array of cellular processes, including growth, differentiation, and immune homeostasis (Huang et al., 2022, Nature Reviews Drug Discovery). The pathway is activated when TGF-beta ligands bind to the type II receptor, which then recruits and phosphorylates the type I receptor, initiating a signaling cascade primarily mediated by SMAD proteins (UniProt P36897). In healthy tissues, TGF-beta acts as a potent tumor suppressor by inhibiting cell proliferation; however, in advanced cancers, it often promotes epithelial-mesenchymal transition (EMT), metastasis, and immune evasion (Batlle & Massagué, 2019, Immunity). Beyond oncology, dysregulation of TGF-beta signaling is a primary driver of various fibrotic diseases, such as pulmonary fibrosis and systemic sclerosis, as well as cardiovascular conditions like Marfan syndrome (Akhurst, 2017, Cold Spring Harbor Perspectives in Biology). Therapeutic strategies include monoclonal antibodies that neutralize ligands, small molecule inhibitors targeting the TGFBR1 kinase domain, and bifunctional fusion proteins designed to simultaneously block TGF-beta and immune checkpoints (Teicher, 2021, Pharmacology & Therapeutics). Despite its therapeutic potential, targeting this pathway is challenging due to its pleiotropic nature, with safety concerns including the development of skin lesions and potential cardiotoxicity (Anderton et al., 2011, Toxicologic Pathology).

Other names

TGFBTGF-beta signaling pathwayTGF-beta superfamilyTransforming growth factor beta receptorTGF-beta signaling complex

Drugs targeting this pathway typically function by neutralizing the TGF-beta ligands (monoclonal antibodies), blocking the receptor's kinase activity (small molecule inhibitors), or acting as 'traps' that sequester ligands away from their cognate receptors (Teicher, 2021, Pharmacology & Therapeutics).